Table 5.
EQ-5D-3 L (Utility) | SF-6D (Utility) | SF-12 PCS (Utility) | SF-12 MCS (Utility) | SGRQ Symptoms score (Utility) | SGRQ Activity score (Utility) | SGRQ Impact score (Utility) | SGRQ Total score (Utility) | |
---|---|---|---|---|---|---|---|---|
EQ-5D-3 L (Utility) | 1.00 | |||||||
SF-6D (Utility) | 0.77 | 1.00 | ||||||
SF-12 PCS | 0.60 | 0.62 | 1.00 | |||||
SF-12 MCS | 0.49 | 0.67 | −0.07 | 1.00 | ||||
SGRQ Symptoms Score | −0.35 | −0.43 | −0.30 | −0.39 | 1.00 | |||
SGRQ Activity Score | −0.38 | −0.44 | −0.46 | −0.19 | 0.58 | 1.00 | ||
SGRQ Impact Score | −0.47 | −0.52 | −0.43 | −0.35 | 0.71 | 0.77 | 1.00 | |
SGRQ Total Score | −0.45 | −0.52 | −0.46 | −0.31 | 0.78 | 0.91 | 0.95 | 1.00 |
Correlation Coefficients in bold were not significant at 95 % confidence